The global canine lymphoma treatment market is expected to grow at a significant CAGR during the forecast period (2021-2027). Malignant lymphoma or lymphosarcoma is one of the most prevalent tumours in dogs, accounting for between 7-24% of all canine tumours and 83% of all canine blood cell malignancies. The primary driver of the market is the increased occurrence of canine lymphoma and the development of breeds with a high incidence of lymphoma, such as Boxers, Bull Mastiffs, Basset Hounds, Saint Bernards, Scottish Terriers, Airedales, and Bull dogs. In 2017-2018 APPA survey, the dogs adopted from a shelter or rescue were 44% of the US household. Moreover, the population of pet dogs has also increased significantly over the past years. It was estimated that there were 89.7 million dogs in 2017-2018 in the US.
To Request a Sample of our Report on Global Canine Lymphoma Treatment Market: https://www.omrglobal.com/request-sample/canine-lymphoma-treatment-market
Another driver of the canine lymphoma treatment market is the increasing expenditure of pet care. Moreover, the total spending on veterinary care & product sales in the US is expected to be nearly around $3.4 million in 2020. This highlights the fact, that the population in the US, is aware of pet health and the necessary measures that are required to be taken to improve their health. This is expected to create significant opportunities for the growth of the market in the US in the future. Moreover, the visit to veterinarians per pet per year were remained fairly stable in the past decade. According to AVMA, for dogs, it was nearly 1.5 times per dog, 0.1 times per bird. In 2016, 78.8% of dog owners were reported to have annual treatment with their veterinarian as compared to 47.2 % of cat owners. As the awareness among the population for pets increases, demand for canine lymphoma treatment is expected to increase across the country, thereby, promoting the growth of the market in near future. However, the market for canine lymphoma treatment is hampered by factors such as high costs and poor animal rights and regulations in underdeveloped countries. Canine cancer costs between $5,150 and $20,000 to treat, according to Pet Insurance. This, in turn, is expected to hinder the market growth.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Oasmia Pharmaceutical AB, VetDC, and Merck & Co., Inc., among others.
(Get 15% Discount on Buying this Report)
A full Report of Global Canine Lymphoma Treatment Market is Available at: https://www.omrglobal.com/industry-reports/canine-lymphoma-treatment-market
Global Canine Lymphoma Treatment Market Report by Segment
By Drug Type
• Alkylating Agents
• Corticosteroids
• Purine Analogs
• Others (Antimetabolites and Immune Modulators)
By Lymphoma Type
• Multicentric Lymphoma
• Alimentary Lymphoma
• Others (Mediastinal Lymphoma)
Global Canine Lymphoma Treatment Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
